Opiant Pharmaceuticals - About the company
Opiant Pharmaceuticals is an acquired company based in Santa Monica (United States), founded in 2005. It operates as a Developer of therapeutics for the treatment of addictive and eating disorders. Opiant Pharmaceuticals has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 53 active competitors, including 14 funded and 15 that have exited. Its top competitors include companies like Indivior, Ethypharm and Amygdala Neurosciences.
Company Details
Developer of therapeutics for the treatment of addictive and eating disorders. The lead drug is NARCAN Nasal Spray for the treatment of opioid overdose. Also developing a treatment for binge eating disorder, and a treatment for cocaine use disorder.
- Website
- opiant.com/en
- Social
- Email ID
- *****@opiant.com
- Registered Address
- Santa Monica, California
Key Metrics
Founded Year
2005
Location
Santa Monica, United States
Stage
Acquired
Latest Funding Round
Last Known Valuation
$***** as on Nov 13, 2022
Investors
Ranked
10th among 53 active competitors
Employee Count
10 as on Mar 31, 2026
Exit Details
Acquired by Indivior (Nov 13, 2022)
Legal entities associated with Opiant Pharmaceuticals
Opiant Pharmaceuticals is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
LIGHTLAKE THERAPEUTICS INC. CIN: 1385508 , United States, Active | $47.8M (As on Dec 31, 2021) | - | - | |
OPIANT PHARMACEUTICALS INC CIN: 464744124 , United States, Active | Dec 26, 999 | - | 31 (As on Dec 31, 2022) | - |
Indivior PLC CIN: 52-2069631501 , United States, Active | Nov 11, 2014 | - | 1051 (As on Dec 31, 2023) | - |
Opiant Pharmaceuticals's acquisition details
Opiant Pharmaceuticals got acquired by Indivior on Nov 13, 2022. It was facilitated by Lazard, Latham & Watkins, Covington & Burling and 1 more.
Click here to take a look at Opiant Pharmaceuticals's acquisition in detail
Sign up to download Opiant Pharmaceuticals' company profile
Opiant Pharmaceuticals's funding and investors
Opiant Pharmaceuticals has raised funding over 4 rounds. Its first funding round was on Mar 07, 2016. Its latest funding round was a Grant (prize money) round on Aug 09, 2022 for $*****. 2 investors participated in its latest round. Opiant Pharmaceuticals has 5 institutional investors.
Here is the list of recent funding rounds of Opiant Pharmaceuticals:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 09, 2022 | 3073728 | Grant (prize money) | 5150322 | 3945309 | 3111266 | 4504700 |
Dec 10, 2020 | 6101708 | Post IPO | 6132366 | 3682968 | 6289348 | |
Jan 02, 2018 | 1989454 | Post IPO | 9636940 | 7832535 | 4516864 | 1515097 |
Access funding benchmarks and valuations. Sign up today!View details of Opiant Pharmaceuticals's funding rounds and investors
Opiant Pharmaceuticals' founders and board of directors
Founder? Claim ProfileOpiant Pharmaceuticals' employee count trend
Opiant Pharmaceuticals has 10 employees as of Mar 26. Here is Opiant Pharmaceuticals's employee count trend over the years:
Uncover Opiant Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Opiant Pharmaceuticals's Competitors and alternates
Top competitors of Opiant Pharmaceuticals include Indivior, Ethypharm and Amygdala Neurosciences. Here is the list of Top 10 competitors of Opiant Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Indivior 2014, Richmond Hill (United States), Public | Therapeutics for addiction treatment | - | 67/100 | |
2nd | Developer of therapies for the treatment of pain and addiction | $248M | 59/100 | ||
3rd |  Amygdala Neurosciences 2015, San Francisco (United States), Series A | Developing medicines for substance use disorders, improving patient lives | $7.05M | 54/100 | |
4th | Myosin Therapeutics 2020, Jupiter (United States), Seed | Developer of therapeutics for CNS-based disorders | $6M | 53/100 | |
5th |  PleoPharma 2020, Phoenixville (United States), Series B | Developer of therapeutics to treat psychiatric diseases | $53.3M | - | 52/100 |
6th | Titan Pharma 1992, San Francisco (United States), Public | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | - | 50/100 | |
7th |  Adial Pharmaceuticals 2010, Charlottesville (United States), Public | Developer of therapeutics for the treatment of addictions | $7.7M | 50/100 | |
8th | DemeRx 2010, Miami (United States), Series A | Developer of non-addicting alternatives for opioid de-addiction | $5.43M | - | 48/100 |
9th | Achieve Life Sciences 1991, Seattle (United States), Public | Developer of plant-based alkaloid for treating smoking cessation | - | 47/100 | |
10th | Opiant Pharmaceuticals 2005, Santa Monica (United States), Acquired | Developer of therapeutics for the treatment of addictive and eating disorders | - | 39/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Opiant Pharmaceuticals's competitors? Click here to see the top ones
Opiant Pharmaceuticals's Investments and acquisitions
Opiant Pharmaceuticals has made no investments or acquisitions yet.
News related to Opiant Pharmaceuticals
Filter this list•
•
•
Indivior raises 2023 revenue forecast following Opiant acquisitionMorningstar•Apr 27, 2023•Indivior, Opiant Pharmaceuticals
•
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.PR Newswire•Mar 02, 2023•Indivior, Opiant Pharmaceuticals
•
Indivior's proposed takeover of NASDAQ firm edges closerInsider Media•Feb 07, 2023•Opiant Pharmaceuticals, Indivior
•
Opiant wins FDA priority review for opioid overdose therapySeeking Alpha•Jan 20, 2023•Opiant Pharmaceuticals
•
•
•
Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing InvestigationsPR Newswire•Dec 14, 2022•, Equillium, Imago BioSciences, Metacrine and 1 other
•
Lifshitz Law PLLC Announces Investigations of ELVT, OPNT, WAFD and LBCThe Wall Street Journal•Dec 11, 2022•Lifshitz Law PLLC, Elevate, Opiant Pharmaceuticals, WAFD Bank and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Opiant Pharmaceuticals
Explore our recently published companies
- Ford Country - Henderson based, 1996 founded, Unfunded company
- A2Z Creations - Panipat based, 2015 founded, Unfunded company
- IRG Commercial - Altamonte Springs based, 1989 founded, Unfunded company
- GMR Quality Stone Products - Sterling Heights based, 2002 founded, Unfunded company
- Socalweb - Los Angeles based, 2004 founded, Unfunded company
- The Darnell Works Agency - Asheville based, 2000 founded, Unfunded company
